Historic Acquisition by Johnson & Johnson

In a landmark move, Johnson & Johnson has announced its agreement to purchase Intra-Cellular Therapies Inc. for an astounding $14.6 billion, marking a significant expansion in its neuroscience portfolio. This acquisition, priced at $132 per share in cash, is poised to redefine the landscape of neuropsychiatric and neurodegenerative disorder treatments.

Funding and Future Plans

The financial structuring of this deal involves a mix of cash reserves and debt, showcasing J&J's strategic approach to funding. An update regarding the acquisition's impact on J&J's adjusted earnings per share is eagerly anticipated during the upcoming fourth-quarter earnings call on January 22.

Commitment to Neuroscience

Joaquin Duato, CEO of Johnson & Johnson, emphasized the company's dedication to advancing neuroscience research and treatment. "This acquisition underscores our commitment to transforming care and pioneering research in challenging neuropsychiatric and neurodegenerative disorders," Duato stated.

Following the announcement, Intra-Cellular Therapies' shares experienced a significant surge, increasing by 34.61% in premarket trading, reflecting the market's positive reception of this deal.